U lcerative colitis (UC) affects the colon and rectum and manifests as continuous areas of inflammation without any segments of normal mucosa. 1 UC is characterized by chronic and relapsing colonic inflammation of unknown etiology and is associated with a substantial risk of colon cancer. 2 The duration of UC is an important factor that is closely linked to cancer risk. 3 UCassociated colon cancer differs from sporadic colon cancer as it develops through the dysplasia-carcinoma pathway. Research shows that the underlying mechanisms that are responsible for UC-associated tumorigenesis include rapid cell turnover and oxidative injury due to chronic inflammation. 4 Aberrant DNA methylation is an important mechanism in the development of many types of cancers. Global DNA hypomethylation in repetitive sequences is thought to contribute to carcinogenesis by inducing genomic instability, 5 whereas regional hypermethylation at promoter CpG islands (CGIs) also plays a key role in carcinogenesis through the inactivation of tumor-suppressor genes. 6 In addition, DNA methylation changes have been reported in aged or inflamed nonneoplastic tissues, which are associated with the occurrence of cancer. 7 In UC, a high degree of CGI hypermethylation is observed in inflamed and dysplastic colonic tissues and forms an "epigenetic field defect" that is linked to a predisposition to colon cancer. 4, 7 Analyses of DNA methylation in UC have primarily been limited to examinations of well-known single genes or subsets of genes; indeed, these analyses have allowed us to better interpret the roles of individual genes in UC-associated tumorigenesis. [7] [8] [9] [10] [11] However, recent advances in genome-wide DNA methylation analyses of the colonic tissues of patients with UC have demonstrated widespread epigenetic drifting. 12 To better characterize the changes in methylation that result from chronic inflammation and lead to the development of cancerous UC, we quantified the DNA methylation of inflamed and noninflamed UC colonic mucosae using candidate panels of 45 CpG promoters and a LINE1 repetitive element. We also used the Infinium HumanMethylation450 BeadChip array to characterize the methylation status of .450,000 CpG sites across the genome.
METHODS

Tissue Samples
We used genomic DNA samples of 94 colonic biopsies from 84 cancer-free patients with UC who underwent colonoscopy at the Fujita Health University Hospital (Toyoake, Japan). Eighty-four of the 94 samples were from inflamed mucosae of the rectum, and the remaining 10 were paired samples from the normal-appearing proximal colons (cecum and ascending and transverse colons) of 10 cancer-free patients with UC. These patients included 47 men and 37 women. The median age and clinical duration were 35 and 5 years, respectively. Six cases eventually underwent surgery due to toxic megacolon. All UC cases were clinically in remission at the time of endoscopy. The histopathological examinations revealed mild or moderate inflammation, but no evidence of dysplasia or neoplasia at any of the sites from which the biopsies were taken. Based on the appearances during endoscopy, 20 patients exhibited inflammatory mucosae only in the rectum, and 38 patients exhibited extensions of the inflammatory mucosae into the left side of the colon (sigmoid and descending colons). The remaining 36 patients exhibited extensions of the inflammatory mucosae into proximal sites (the transverse and ascending colons and the cecum). We also used the Mayo endoscopic subscore to evaluate the endoscopic appearances at the sites from which the colonoscopic biopsies were taken. 13 Each score was based on the endoscopic findings as follows: 0, normal or inactive disease; 1, mild disease (erythema, decreased vascular pattern, and mild friability); 2, moderate disease (marked erythema, absent vascular pattern, friability, and erosions); and 3, severe disease (spontaneous bleeding and ulcerations). This cohort was recruited from our previous studies that investigated the associations of DNA methylation with clinical phenotypes, host genetic factors, and telomere lengths. [14] [15] [16] Genomic DNA was also obtained from 14 neoplastic colorectal lesions (5 highgrade dysplasias and 9 carcinomas) and 8 adjacent tissues from 12 patients who underwent surgery or colonoscopy at the Fujita Health University Hospital (Toyoake, Japan). These patients included 8 men and 4 women with a median age of 45 years. The characteristics of cancer-free UC patients and UC patients with neoplastic lesions are summarized in the Table 1 . This study was approved by the Human Research Ethics Committee of the Fujita Health University School of Medicine. Each participant provided written informed consent for the use of his or her clinical and laboratory data for publication and research purposes. The study was conducted according to the principles outlined in the Declaration of Helsinki.
Selection of Candidate Panels and CpG Methylation Analysis by Bisulfite Pyrosequencing
Bisulfite-treated genomic DNA was used to evaluate the methylation status of 45 CGIs. We used 2 approaches to select the genes (all genes were selected from the literature). The first approach was based on the frequencies of methylation in digestive cancers, and the selected genes were MINT1, 2, 12, 25, and 31, RARB2, IGF2, ADAM23, RORA, GDNF, PRDM5, MLF1, p16, SOX11, SOX17, MYO3A RASSF1A, MGMT, hTERT, MIR671, DPYS, NKX2-5, SLC16A12, SPOCK2, GARA2, and GSTP1 [17] [18] [19] [20] [21] The second approach was based on methylation in nonneoplastic inflamed/aged tissues and identified the following genes: ER, CDH1, CDH13, MYOD1, SFRP1, HPP1, P2RX7, N33, MIR124A1, MIR124A3, MIR34BC, MIR1247, NEOUROG1, CDX1, DOK5, MDR1 HOXD13, HAND2, and HOXA4. [7] [8] [9] [17] [18] [19] 22 We also evaluated the methylation status of the LINE1 repetitive element. Bisulfite-treated genomic DNA was used to evaluate the methylation status by bisulfite pyrosequencing. The bisulfite treatment of the DNA was performed with an EpiTect Bisulfite Kit (QIAGEN, Tokyo, Japan) according to the manufacturer's protocol. Pyrosequencing was performed using a PSQ24 system with a Pyro-Gold Reagent kit (QIAGEN, Tokyo, Japan), and the results were analyzed using PyroMark Q24 software (QIAGEN). The primers used for pyrosequencing are listed in Supplementary Table 1 (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B420). The pyrosequencing experiments were performed for all 45 CGIs and LINE1 in 94 colonic biopsies from 84 cancer-free patients with UC. Because of limited availability of genomic DNA, the pyrosequencing experiments were performed for 5 CGIs (i.e., DPYS, N33, MIR1247, GSTP1, and SOX11) of the DNA samples of 14 neoplastic colorectal lesions (5 with high-grade dysplasia and 9 with carcinomas) and 8 adjacent tissues from 12 patients with neoplastic colorectal lesions.
Genome-Wide Methylation Analysis
To fully determine the methylation changes that occurred in the colonic inflammatory mucosae of the patients with UC, we performed array-based DNA methylation analyses using the Infinium HumanMethylation450 BeadChip array, which allowed us to query the methylation status of .450,000 CpG sites within the genome and to cover 99% of the RefSeq genes. Genomic DNA samples from the inflamed rectal mucosae of 10 patients with UC were used for this analysis. One patient had high-grade dysplasia in the rectum. This patient also presented with a severe clinical course of continuing severe chronic inflammation, steroid dependency, and duration of over 7 years at the time of the diagnosis of high-grade dysplasia. The other 5 cases did not have neoplastic lesions but presented with severe clinical courses as illustrated by the case with high-grade dysplasia. The durations of these cases were also more than 7 years. The remaining 4 cases presented with very mild clinical courses and durations less than 7 years. Bisulfite modification of the genomic DNA was performed using an EZ DNA Methylation Kit (Zymo Research). The bisulfite conversion efficiency was determined based on sample-dependent controls on the chip and was displayed in the quality control panel in the software. We removed probes that were targeted for an annotated singlenucleotide polymorphism (dbSNP137) and for either the X or Y chromosome. Information about the CGIs and promoters (surrounding gene transcription start sites) was also obtained based on the GRCh37/hg19.
Clustering Analysis
Unsupervised clustering analysis using ArrayTrack (http:// www.fda.gov/ScienceResearch/BioinformaticsTools/Arraytrack/) was performed to identify distinct subgroups based on the methylation status.
Gene Ontology Analysis
Functional enrichment of the methylated genes was determined by gene ontology analysis using DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov/). P-values were corrected for multiple hypotheses testing using the Benjamini method.
Statistical Analysis
The continuous variables were compared between 2 and more groups using Student's t tests and the one-way analysis of variance, respectively. The correlations of continuous variables between the 2 groups were assessed using Spearman correlation analyses. P values ,0.05 were considered statistically significant.
RESULTS
The Methylation Status of the Candidate Genes Distinguished the Inflammatory Samples from the Noninflammatory Samples Figure 1 illustrates the results of an unsupervised clustering analysis of 45 candidate genes and the LINE1 repetitive element. For this analysis, we examined the paired inflammatory and noninflammatory colonic mucosae of 10 patients. The results demonstrated that most inflammatory rectal mucosae clearly clustered as hypermethylated samples relative to the noninflammatory proximal mucosae. One noninflammatory sample (85N) clustered as a relatively hypermethylated sample; however, the inflammatory FIGURE 1. Unsupervised hierarchical clustering analysis of candidate genes using paired normal and inflamed colonic mucosa derived from 10 cancer-free patients with UC. Black boxes, inflammatory rectal mucosa (R); blue boxes, normal proximal mucosa (N); Samples of the same ID number were obtained from the same patients.
rectal sample from the same patient (85R) exhibited greater hypermethylation in this case. Therefore, hypermethylation was observed in the inflammatory rectal samples compared with the noninflammatory proximal mucosae in all 10 cases.
The Methylation Status of the Candidate Genes Closely Correlated with Disease Duration
Because accelerated DNA methylation was observed in the inflammatory rectal mucosae of the patients with UC, we next sought to determine whether this methylation was associated with the duration or severity of inflammation. Among the rectal samples from the cancer-free cases, we found that the accelerated methylation of many genes was closely correlated with longer disease duration. These genes included SOX17, CDH13, DPYS, MLF1, SOX11, GDNF, N33, and SCL16A12 (Fig. 2) . Among all 45 candidate genes, positive and significant (at the level of P ,0.01) correlations were observed for 16 genes (data not shown). Unsupervised hierarchical clustering analysis of these 16 genes demonstrated that the rectal mucosa samples associated with longer durations (.10 years) predominantly clustered as the hypermethylated samples compared with the mucosa samples associated with shorter durations (;10 years; see Fig. S1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B420). As expected, the mean methylation Z score of these 16 genes was also positively correlated with the disease duration (Fig. 3) . However, we did not observe significant associations of the methylation of these genes or the mean methylation Z score with the Mayo endoscopic subscore, which is an indicator of the severity of mucosal inflammation (Figs. 3 and see Fig. S1 , Supplemental Digital Content 1, http:// links.lww.com/IBD/B420). We also evaluated whether the methylation status correlated with other conventional indicators of the severity of current inflammation, such as the C-reactive protein, white blood cell count, and erythrocyte sedimentation rate. However, these correlations were limited to the methylation of the MIR1247 and CDH1 genes with the more severe Mayo endoscopic subscores (P ¼ 0.0008 and 0.03, respectively 14 ).
Because longer disease duration is a risk factor for the development of neoplastic lesions in UC, 3 we next asked whether the DNA methylation observed in the cases with longer durations were associated with the occurrence of neoplastic lesions. For this analysis, we used genomic DNA from 14 neoplastic colorectal lesions (5 high-grade dysplasias and 9 carcinomas) and 8 adjacent tissues from 12 patients. Due to limited availability of genomic DNA from these patients, the methylation analyses were restricted to the 5 genes that were related to duration. We observed hypermethylation of 2 genes (DPYS and N33) among the UC samples with neoplasias (Fig. 4) . Notably, the methylation of DPYS and N33 and their mean Z score were higher in both the neoplastic and adjacent tissues of the patients with UC with neoplasias, which suggests that the hypermethylation of these genes and their mean Z score may predict the occurrence of neoplastic lesions in UC.
The Genome-Wide Methylation Status of CGIs Distinguishes Severe Phenotype UC
To fully determine the methylation changes that occurred in the colonic inflammatory mucosae of the patients with UC, we used an Infinium HumanMethylation450 BeadChip array, which FIGURE 2. Association between DNA methylation and duration of UC in 84 cancer-free patients with UC. Statistical analysis was performed using Spearman correlation analysis. All P values ,0.05. allowed us to query the methylation status of .450,000 CpG sites within the genome. This experiment was performed specifically in an attempt to determine the methylation changes that occurred in the cases who were at higher risks of developing neoplastic lesions. We used 1 rectal sample from a case with high-grade dysplasia. In addition, we evaluated 5 samples from patients with longer disease duration and severe clinical courses (including severe chronic inflammation, steroid dependency, and frequent hospitalization) because these cases were also at greater risk for the development of neoplastic lesions. Together, these 6 cases were defined as severe phenotype cases. For the comparative samples, we used 4 cases who presented with mild clinical courses and disease durations of less than 7 years. Based on GRCh37/hg19, we first checked the methylation status of 473,864 CpG sites and divided the sites into CGIs (n ¼ 145,842) and non-CGIs (NCGI: n ¼ 328,022). We found that accelerated methylation among the severe phenotypes was more striking at the CGI sites than the NCGI sites (Fig. 5) . Unsupervised clustering analysis using the 10% of the probes with the greatest variation very clearly distinguished the samples from the severe phenotype patients in both the promoter CGIs (PCGI: n ¼ 1810) and outside the promoters (NPCGI: n ¼ 17,554). The samples from the severe phenotype cases, including 1 case with high-grade dysplasia (107R), were clustered together as the hypermethylated samples (Fig. 6) . In contrast, analyses of the NCGIs using the same criteria resulted in the clustering of the severe phenotypes into a group of samples that were hypomethylated samples in the promoter NCGIs (PNCGI: n ¼ 2883) and outside the promoter NCGIs (NPNCGI: n ¼ 6301). However, this analysis did not clearly distinguish the severe and mild phenotypes compared with the distinction based on the CGIs (see Fig. S2 , Supplemental Digital Content 1, http://links.lww.com/IBD/B420).
Identification of the Hypermethylated PCGIs in the Severe Phenotypes
We next explored genes that were exclusively hypermethylated in cases with severe phenotypes. For this analysis, we focused on the PCGIs because of their influence on gene expression. 6 When a gain in methylation was defined as a methylation level $20% (b-value $ 0.2), the numbers of methylated PCGIs among the severe-phenotype cases ranged from 2135 to 2468, and these values were significantly greater than those of the mild phenotypes (2875-4079: severe versus mild P , 0.01: Fig. 7 ). To determine whether there was any functional enrichment of the genes that were exclusively hypermethylated in the severe phenotypes, we performed an additional search for hypermethylated genes among the severe phenotypes. We searched for genes that were methylated in at least 2 severe cases but exhibited methylation levels ,5% in all the mild cases and identified 95 genes. Gene Ontology analysis using DAVID revealed that these genes are involved in biosynthetic processes (P ¼ 5.69E-05), the regulation of metabolic processes (P ¼ 0.009), and nitrogen compound metabolic processes (P ¼ 0.015; Fig. 8 and see Fig. S2 , Supplemental Digital Content 1, http://links.lww.com/IBD/B420). Notably, the hypermethylated genes involved in these processes frequently coded for zinc finger proteins, such as ZNF582, ZNF614, ZNF274, ZNF583, and ZNF559 (see Fig. S2 , Supplemental Digital Content 1, http://links.lww.com/IBD/B420).
DISCUSSION
UC is a disease that is characterized by chronic inflammation, rapid cell turnover, and a substantial risk of colon cancer. The unique pathology of this disease provides an opportunity to examine dynamic molecular processes, such as epigenetic changes. Initially, we demonstrated that the rectal inflammatory mucosa in UC is characterized as hypermethylated at multiple PCGIs. Previous studies have revealed that accelerated DNA methylation is observed in the inflamed colonic epithelium in UC. However, the majority of these data were limited to those collected from examinations of subsets of genes. [7] [8] [9] [10] [11] We characterized the methylation status of the inflammatory colonic mucosa in UC using the PCGIs of 45 candidate genes and the LINE1 repetitive element. This panel covered the known genes where methylation was reported in both cancerous and inflamed/aged tissue. [7] [8] [9] [17] [18] [19] These data suggest that methylation induction in the inflammatory mucosa in UC occurs in many groups of CGI promoters rather than only in a subset of genes. UC is diverse in its clinical course and prognosis, and individual differences in inflammatory status are likely relevant to this heterogeneity. We have demonstrated that methylation status was strongly associated with longer UC duration, which is a known risk factor for colorectal cancer. These genes included well-known age-related genes in the colon (N33 and ER 17 ) in addition to genes whose methylation are associated with epigenetic field defects in inflammationassociated cancers, such as gastric (CDH13, MIR124A1, MIR124A3, and MIR34bc 19 ) and UC-associated colon cancers (N33, ER, MIR124A1, and MIR124A3 [7] [8] [9] 23 ). Several other genes related to the duration of UC were characterized as methylated in colon cancer, but their methylation levels were also detectable (;10%) in the adjacent mucosae (i.e., SLC16A12, SPOCK2, GARA2, and NKX2.5 18 ). Taken together, our results indicate that genes may play important roles in epigenetic field defects in UC. Importantly, these genes did not include genes that are wellknown to exhibit colorectal cancer-specific methylation, such as MINT1, 2, 12, and 31, and p16, 17 which indicates the importance of discriminating between cancer-specific methylation and inflammation/age-related methylation. 24 In contrast, we did not observe any positive associations of the Mayo endoscopic subscore, which is an indicator of the severity of mucosal inflammation, with the methylation status of the group of genes whose hypermethylation were correlated with longer UC duration. When the analyses were extended to all 45 genes, correlations of the methylation status with the Mayo endoscopic subscores were limited to only a subset of genes, including MIR1247 and CDH1. 14 These findings suggest the importance of the duration of inflammation rather than the degree of current inflammation to the epigenetic field defect. Among the genes with methylation that were related to duration, the methylation of DPYS and N33 were higher in the neoplastic UC tissues. Notably, the methylation was also higher in the tissues adjacent to the neoplasias in the patients with UC. N33 has previously been reported to be highly methylated in dysplastic epithelia from patients with high-grade dysplasia/cancer with UC. 8 One weakness of our study was the limited availability of genomic DNA, which restricted the number of genes that could be analyzed. Whether analyses of DNA methylation can predict the risk of UC-associated neoplasias should be evaluated with additional integrated methylation analyses.
To understand the methylation changes that resulted from chronic inflammation and potentially led to cancer development more in depth, we performed a genome-wide methylation analysis. Our findings demonstrated a surprisingly high rate of hypermethylation in the severe phenotype of UC, particularly at the CGIs. The clustering of the 10% of the probes that exhibited the greatest variation at the CGIs clearly discriminated the severe and mild phenotypes. When we focused on the NCGIs, hypomethylation seemed to be the typical pattern of UC with the severe phenotype, but the NCGI methylation did not separate the severe and mild phenotypes as clearly. Our data suggest that in UC, methylation alterations that are related to the epigenetic field defect can be characterized as hypermethylation of CGIs. We have demonstrated the tight clustering of the severe phenotype both in terms of promoters and regions outside PCGIs. These findings indicate the importance of the hypermethylation of PCGIs to the epigenetic field defect in UC. Moreover, these results also raise the possibility that underlying mechanisms that induce DNA methylation throughout the CGIs in UC exist. For example, the expression of DNA methyltransferase (DNMT)-1, which is an important enzyme for maintaining methylation status during DNA replication, increases gradually from the rectal mucosae of patients with UC without neoplasias to the nonneoplastic rectal mucosae of patients with UC with neoplasia and to colorectal neoplasias. 25 We have demonstrated that the hypermethylated PCGIs in the severe phenotypes exclusively and frequently were the promoter genes that code for proteins involved in biosynthetic processes, the regulation of metabolic processes, and nitrogen compound metabolic processes. The genes involved in these processes code for proteins that contained zinc fingers, such as ZNF582, ZNF614, ZNF274, ZNF583, and ZNF559. Importantly, the hypermethylation of these genes have been reported in several cancers, including colon (ZNF582 and ZNF583 26, 27 ), cervical (ZNF614 28 ), and gastric cancers (ZNF559 29 ).
The hypermethylation of ZNF274 has also been reported in nonalcoholic fatty liver disease, which is a known risk factor for liver cancer. 30 A recent genome-wide methylation analysis of pediatric patients with UC revealed epigenetic changes in genes related to colonic mucosal immune and defense responses that were not found in our study. 12 This discrepancy highlights the differences in methylated genes between the processes of disease onset and carcinogenesis. The discovery of the frequent methylation of genes that code for zinc finger proteins emphasizes the importance of an improved understanding of pathway-specific molecular changes in UC-related tumorigenesis and raises the possibility that specific epigenetic therapies that target alterations in zinc finger proteins could be useful in the treatment and chemoprevention of UC-related colorectal cancer.
